For instance, the combination of TC (carboplatin and paclitaxel) plus trastuzumab has demonstrated increased progression-free survival (PFS) (HR = 0.46; 90% CI, 0.28-0.76) and overall survival (OS) (HR=0.58; 90% CI, 0.34–0.99) in patients with advanced or recurrent uterine-serous-carcinoma (USC) exhibiting human epidermal growth factor receptor 2 (HER2) overexpression (175). Here, ERBB2 is linked to endometrial serous adenocarcinoma.